朗姿股份(002612) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥1,399,924,809.17, representing an increase of 11.42% compared to ¥1,256,386,872.51 in the same period last year[17]. - Net profit attributable to shareholders was ¥82,171,699.62, up 15.83% from ¥70,940,701.73 year-on-year[17]. - The net profit after deducting non-recurring gains and losses was ¥78,696,979.55, reflecting a 25.02% increase from ¥62,947,666.58 in the previous year[17]. - Total operating revenue for the first quarter reached ¥1,399,924,809.17, an increase of 11.4% compared to ¥1,256,386,872.51 in the previous period[29]. - Net profit attributable to the parent company was ¥82,171,699.62, up from ¥70,940,701.73, reflecting a growth of 15.5%[30]. - The company reported a total comprehensive income of ¥57,668,666.96, compared to ¥33,034,869.39 in the previous period, indicating a significant increase[30]. - The basic earnings per share increased to ¥0.1857 from ¥0.1603, representing a growth of 23.5%[30]. Assets and Liabilities - Total assets at the end of the reporting period were ¥7,632,940,211.89, a 1.49% increase from ¥7,520,537,141.78 at the end of the previous year[17]. - The total assets increased to ¥7,632,940,211.89 from ¥7,000,000,000, indicating a growth of approximately 9%[28]. - Total liabilities rose to ¥3,866,506,479.94 from ¥3,702,230,307.96, representing an increase of around 4.43%[42]. - Non-current liabilities totaled ¥1,328,880,721.06, up from ¥1,142,555,934.50, reflecting a growth of approximately 16.3%[42]. - The total equity stood at ¥3,766,433,731.95, compared to ¥3,818,306,833.82, showing a decrease of about 1.36%[42]. - The equity attributable to shareholders was ¥3,062,527,473.89, showing a decrease of 1.09% from ¥3,096,227,961.02 at the end of the previous year[17]. Cash Flow - The net cash flow from operating activities decreased by 12.78% to ¥213,985,160.52 from ¥245,337,026.57 in the same period last year[17]. - Operating cash inflow from sales reached ¥1,411,932,174.18, compared to ¥1,278,284,630.95 in the previous period, marking an increase of about 10.4%[47]. - The net cash flow from operating activities was ¥213,985,160.52, down from ¥245,337,026.57, indicating a decrease of approximately 12.7%[47]. - The net cash inflow from financing activities was CNY 77,803,792.02, a significant improvement compared to a net outflow of CNY 81,904,562.72 in the previous period[32]. - The company reported a cash inflow from financing activities totaling CNY 558,673,730.03, compared to CNY 616,001,014.04 in the previous period[32]. - Cash outflows from financing activities amounted to CNY 480,869,938.01, a decrease from CNY 697,905,576.76 in the previous period[32]. - The company reported a decrease in accounts payable to ¥248,311,570.24 from ¥270,579,926.98, a reduction of about 8.2%[42]. - The net cash flow from investing activities was negative at -¥25,521,981.28, an improvement from -¥86,259,825.42 in the previous period[47]. Investments and Acquisitions - The company completed the acquisition of Zhengzhou Jimei, with the total transfer price for the 100% equity valued at ¥15,515.00 million[13]. - The company plans to acquire 70%, 18%, and 12% equity stakes in Zhengzhou Jimei Medical Beauty Hospital from various investors for cash, indicating a strategic move to expand its market presence[38]. - The company's cash outflow from investing activities was ¥86,969,321.40, compared to ¥28,795,514.46 in the previous period, indicating a significant increase in investment spending[47]. Other Financial Metrics - The company's weighted average return on equity was 2.72%, up from 2.22% in the previous year[17]. - The company reported a significant increase in prepayments, which rose by 178.58% to ¥77,580,399.59 due to increased material procurement[19]. - The company received government subsidies amounting to ¥1,671,454.04, contributing to an 89.56% increase in other income[19]. - Research and development expenses rose to ¥27,516,377.00, compared to ¥23,045,991.84, marking an increase of 19.5%[30]. - Cash received from other operating activities was ¥13,046,058.50, slightly down from ¥14,112,225.30, a decrease of approximately 7.5%[47]. - The cash and cash equivalents at the end of the period were ¥683,984,862.22, up from ¥427,570,588.37, showing a growth of 60%[28]. - The total cash and cash equivalents at the end of the period reached CNY 675,413,862.22, up from CNY 492,766,887.79 at the end of the previous period, indicating a net increase of CNY 258,414,273.85[32]. - The impact of exchange rate changes on cash and cash equivalents was a decrease of CNY 7,852,697.41[32]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 64,311, with the largest shareholder holding 47.82% of the shares[36]. - The largest shareholder, Shen Dongri, holds 211,559,098 shares, of which 158,669,323 are pledged[36]. - The company has a total of 9,420,000 shares held under the third employee stock ownership plan, representing 2.13% of total shares[36]. - The company has not disclosed any related party transactions or financing activities involving the top 10 shareholders[37].